New hope for advanced cancers: OBI-902 trial launches

NCT ID NCT07124117

First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 23 times

Summary

This study tests a new drug called OBI-902 in people with advanced solid tumors that have not been cured by standard treatments. The trial has three parts: first, finding a safe dose; second, checking how well that dose works in certain cancers; and third, comparing different doses to pick the best one for larger studies. About 147 adults will take part, and the main goals are to see if the drug is safe and whether it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China Medical University Hospital

    RECRUITING

    Taichung, 404327, Taiwan

    Contact

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

  • Scripps Green Hospital

    RECRUITING

    La Jolla, California, 92037, United States

    Contact

  • Shuang Ho Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, Zhonghe, 23561, Taiwan

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • Wan Fan Hospital

    RECRUITING

    Taipei, Wenshan, 116, Taiwan

    Contact

Conditions

Explore the condition pages connected to this study.